Which firms invest in microbiome therapeutics?

This blog post has been written by the person who has mapped the microbiome therapeutics market in a clean and beautiful presentation

The microbiome therapeutics investment landscape has evolved into a sophisticated ecosystem where specialized venture capital firms, pharmaceutical giants, and strategic investors compete for promising startups developing gut-based therapies.

Major players like Seventure Partners have committed over €100 million exclusively to microbiome companies, while Johnson & Johnson Innovation has backed 11 different startups in this space through their corporate venture arm. Understanding which firms invest in microbiome therapeutics and their specific investment patterns can provide crucial insights for entrepreneurs seeking funding or investors looking to enter this rapidly growing market.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Who are the top venture capital firms currently investing in microbiome therapeutics?

Seventure Partners dominates the microbiome investment landscape as the world's most active specialized VC firm, having committed over €100 million exclusively to microbiome companies since establishing their microbiome fund.

The French firm has built an impressive portfolio including Enterome Bioscience, Eligo Bioscience, MaaT Pharma, and Sequentia Biotech. In September 2024, Seventure Partners led the €10 million Series A round for Sequentia Biotech, demonstrating their continued commitment to next-generation microbiome analysis platforms.

Johnson & Johnson Innovation (JJDC) represents the most active corporate venture arm in microbiome therapeutics, having backed 11 companies over the past five years. Their portfolio spans multiple therapeutic areas including DayTwo for personalized nutrition, Infinant Health for neonatal probiotics, Holobiome for gut-brain axis research, and Locus Biosciences for precision antibacterial products. JJDC's diversified approach reflects pharmaceutical industry confidence in microbiome applications across multiple disease areas.

Traditional venture capital firms actively investing include Illumina Ventures, which led Pluton Biosciences' $16.5 million Series A round, and the partnership between Khosla Ventures and True Ventures that backed Pendulum Therapeutics' $111 million total funding. RA Capital and OrbiMed maintain multiple microbiome investments in their portfolios, while newer entrants like DCVC and Lions Capital LLC co-led Kanvas Biosciences' recent $12.5 million funding round.

European investors beyond Seventure Partners include Tencent and Flerie Invest, which co-led Microbiotica's £50 million Series B round, and Biocodex, which supports MaaT Pharma's development of Microbiome Ecosystem Therapies. These firms focus on companies developing clinically validated therapeutic approaches rather than early-stage research platforms.

Which specific startups in microbiome therapeutics have received funding recently, and what do these startups do?

Kanvas Biosciences raised $12.5 million in July 2024 to advance their microbiome-based therapeutic pipeline targeting metabolic and inflammatory diseases through engineered bacterial consortia.

MaaT Pharma completed a €13 million capital increase in March 2025 with support from historical shareholders including Biocodex and PSIM Fund. The French clinical-stage company develops Microbiome Ecosystem Therapies (MET) using pooled-donor microbiota delivered via enema, with their lead candidate MaaT013 showing 62% gastrointestinal response rates in acute Graft-versus-Host disease trials.

Sequentia Biotech secured €10 million in Series A funding in September 2024, led by Seventure Partners and co-invested by the EIC Fund. The Barcelona-based bioinformatics company specializes in omics data analysis platforms, including their MICK system that translates complex microbiome data into actionable therapeutic insights for pharmaceutical companies.

32 Biosciences announced $6 million in 2024 funding to support development across their two subsidiaries: Covira, focused on microbiome interventions for inflammatory bowel disease, and Gateway Biome, developing therapies for metabolic disorders. This University of Chicago spinout leverages $119 million in NIH research support for product development.

SNIPR Biome received €20 million in European funding during 2024 to advance their CRISPR-armed phage delivery system (SNIPR001), which demonstrates broad activity against 429 E. coli strains for precision antimicrobial therapy. Ancilia Biosciences secured $4.2 million including $3 million from ARPA-H's Sprint for Women's Health program to develop CRISPR-based bacterial therapies for women's health applications.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

How much funding did each of these firms provide, and in which rounds or stages?

Seventure Partners typically leads Series A rounds in the €10-25 million range, as demonstrated by their €10 million investment in Sequentia Biotech's Series A round alongside the EIC Fund co-investment.

Johnson & Johnson Innovation's investments span multiple stages but focus primarily on Series A and B rounds ranging from $5-30 million per investment. Their backing of Locus Biosciences contributed to the company's total $117.5 million fundraising across multiple rounds, while their DayTwo investment was part of the Israeli startup's $90 million total funding.

Traditional venture capital firms demonstrate varying investment patterns: Khosla Ventures and True Ventures jointly contributed to Pendulum Therapeutics' $111 million total funding across multiple rounds, while DCVC and Lions Capital LLC each provided approximately $6 million in Kanvas Biosciences' latest $12.5 million round. Illumina Ventures led Pluton Biosciences' $16.5 million Series A round as the primary investor.

Corporate venture arms typically invest $10-50 million per transaction: Sanofi Ventures led Eligo Bioscience's $30 million Series B funding round, while Tencent and Flerie Invest co-led Microbiotica's £50 million ($67 million) Series B round. These larger rounds reflect the capital-intensive nature of advancing microbiome therapeutics through clinical development.

Seed-stage funding typically ranges from $2-5 million, with companies like Alba Health raising $2.5 million total funding, Neobe Therapeutics securing $2 million, and Genetic Analysis AS raising $2 million. Series A rounds consistently fall in the $10-25 million range, while Series B and later rounds require $30-100+ million to support clinical trial expenses and regulatory preparation.

What conditions or equity stakes were typically involved in these funding deals?

Specific equity percentages remain confidential in most microbiome therapeutics funding deals, but MaaT Pharma's recent licensing agreement with Clinigen provides insight into typical commercial terms structure in this sector.

The MaaT Pharma-Clinigen deal includes €10.5 million upfront payment, €18 million in regulatory and sales milestones, plus mid-thirties percentage royalties on net sales. This structure reflects the high-risk, high-reward nature of microbiome therapeutics investments, where significant upfront capital supports lengthy clinical development timelines with substantial milestone-based returns upon regulatory approval.

The Seres-Nestlé VOWST acquisition demonstrates exit valuation benchmarks: $175 million upfront plus potential $350 million in future milestones, totaling up to $525 million for a commercially approved microbiome therapeutic. This transaction provides validation for investor return expectations and suggests early-stage equity stakes must account for potential 10-50x returns upon successful commercialization.

Series A investors typically receive 15-25% equity stakes for $10-25 million investments, based on pre-money valuations ranging from $30-75 million for companies with validated preclinical data. Series B investors often invest $30-50 million for 10-20% stakes, reflecting higher valuations of $150-300 million for companies entering or completing Phase I/II clinical trials.

Corporate venture investors often negotiate strategic partnership terms alongside equity investments, including licensing options, manufacturing agreements, or commercialization rights. Johnson & Johnson Innovation's investments frequently include collaboration agreements for target validation, clinical development support, or exclusive licensing negotiations for specific therapeutic indications.

Which countries or regions are most active in investing in microbiome therapeutics?

North America dominates microbiome therapeutics investment activity, holding approximately 73% of global market share with the United States leading in both funding volume and company formation.

California hosts major companies including Pendulum Therapeutics, Whole Biome, and FitBiomics, benefiting from proximity to leading venture capital firms and biotech infrastructure. The Boston/Cambridge corridor represents another critical hub with companies like Holobiome, Finch Therapeutics, and access to world-class research institutions including MIT and Harvard Medical School.

The San Francisco Bay Area provides essential venture capital ecosystem support, with firms like Khosla Ventures, True Ventures, and DCVC actively investing in microbiome startups. This region's concentration of biotech expertise and capital availability creates favorable conditions for early-stage company development and follow-on funding rounds.

Europe represents the second-largest investment region, led by France's sophisticated microbiome ecosystem centered around Seventure Partners. French companies including MaaT Pharma, Enterome Bioscience, and Eligo Bioscience benefit from specialized investor knowledge and government support for biotechnology development. The United Kingdom's Cambridge cluster includes companies like Microbiotica and EnteroBiotix, leveraging strong academic partnerships and European venture capital availability.

Asia-Pacific emerges as the highest growth region, driven by China's $400 million National Microbiome Project launched in 2019 and Japan's significant government funding initiatives. Japanese companies like Metagen Therapeutics are raising substantial funding for fecal microbiota transplantation drug development, while South Korea increases government support and private investment activity in microbiome research applications.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are major pharmaceutical or biotech giants backing microbiome therapeutics startups, and if so, which ones?

Nestlé Health Science made the largest pharmaceutical acquisition in microbiome therapeutics history with their $175 million purchase of VOWST from Seres Therapeutics, demonstrating major corporate commitment to commercially validated microbiome products.

AstraZeneca has invested $3.5 billion in expanding their research footprint and initiated multiple collaborations with microbiome companies, including partnerships with Seres Therapeutics for cancer immunotherapy research combining checkpoint inhibitors with microbiome modulation. Their investment strategy focuses on combination therapies that enhance existing pharmaceutical products through microbiome interventions.

Ferring Pharmaceuticals acquired Rebiotix in 2019, gaining access to the first FDA-approved oral fecal microbiome product for C. difficile infection prevention. This acquisition validated the regulatory pathway for microbiome therapeutics and established Ferring as a leader in this therapeutic category.

Sanofi Ventures led Eligo Bioscience's $30 million Series B funding round, demonstrating the French pharmaceutical giant's commitment to gene editing and microbiome technology platforms. Sanofi's investment strategy targets companies developing synthetic biology approaches to microbiome manipulation for therapeutic applications.

Unilever maintains research partnerships with Holobiome to understand gut-brain axis applications for consumer products, while also investing in microbiome-focused startups like Straand for scalp care applications. Royal DSM (now part of Firmenich) has been identified as one of the most active corporate investors in microbiome startups, focusing on nutrition and health applications that complement their existing product portfolio.

If you want to build or invest on this market, you can download our latest market pitch deck here

What key technologies or R&D breakthroughs in microbiome therapeutics are attracting investment?

Live Biotherapeutic Products (LBPs) represent the most mature and investment-attractive technology platform, with Infant Bacterial Therapeutics achieving a 27% reduction in all-cause mortality for necrotizing enterocolitis in a Phase 3 trial comprising 2,153 premature infants.

This breakthrough represents the first FDA and EMA-approved single-strain LBP, validating the entire field and attracting significant follow-on investment in similar approaches. Companies developing defined bacterial consortia for specific diseases, including Seres Therapeutics, Finch Therapeutics, and Rebiotix, have secured major funding rounds based on this validation.

CRISPR-engineered microbiome therapies attract substantial investment due to their precision and broad applicability. SNIPR Biome's CRISPR-armed phage delivery system (SNIPR001) demonstrates activity against 429 E. coli strains, representing breakthrough precision antimicrobial therapy that received €20 million in European funding during 2024.

AI-driven microbiome analysis platforms capture investor attention by reducing drug discovery timelines and improving success rates. Sequentia Biotech's MICK platform provides state-of-the-art data analysis for microbiome research, translating complex microbial data into actionable therapeutic insights that pharmaceutical companies require for efficient product development.

Microbiome Ecosystem Therapies (MET) developed by companies like MaaT Pharma represent a novel therapeutic class using pooled-donor microbiota delivered via enema. MaaT013 demonstrates 62% gastrointestinal overall response rates and 54% one-year overall survival in acute Graft-versus-Host disease, attracting €13 million in recent funding for clinical advancement. Synthetic biology platforms combining diagnostic and therapeutic functions, including iROBOT therapy systems that sense inflammatory signals and target corresponding tissues, represent the cutting edge of intelligent bacterial therapeutics attracting venture capital investment.

How much total funding was raised in the microbiome therapeutics sector in 2024?

The microbiome therapeutics sector raised approximately $80-100 million in disclosed funding rounds during 2024, representing continued investment activity despite broader biotech funding challenges.

Major transactions included Kanvas Biosciences raising $12.5 million, SNIPR Biome securing €20 million (~$22 million), Sequentia Biotech completing a €10 million (~$11 million) Series A round, Holobiome raising $9 million, 32 Biosciences announcing $6 million in funding, and Ancilia Biosciences securing $4.2 million including significant government support.

Early-stage deals dominated 2024 funding activity, with average deal sizes remaining relatively small compared to other therapeutic areas. This pattern reflects investor focus on companies with validated scientific approaches rather than speculative early-stage research, indicating market maturation and increased due diligence standards.

The funding distribution favored companies with clinical validation or clear regulatory pathways: SNIPR Biome's €20 million represented the largest single funding round, supporting their CRISPR-engineered approach with demonstrated antimicrobial activity across hundreds of bacterial strains. Sequentia Biotech's €10 million Series A funding reflected investor confidence in AI-driven analysis platforms that support multiple pharmaceutical company partnerships.

Geographic distribution of 2024 funding favored European companies, with approximately 60% of disclosed funding going to European startups including SNIPR Biome, Sequentia Biotech, and other Seventure Partners portfolio companies. North American companies captured the remaining 40%, with Kanvas Biosciences and 32 Biosciences representing the largest US-based funding rounds during the year.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

How much has been raised so far in 2025 in this space?

Early 2025 has demonstrated continued momentum in microbiome therapeutics funding with several significant transactions through July, including MaaT Pharma's €13 million capital increase, Enterome's $19 million funding round, and PreciseDx securing $11 million in additional funding.

MaaT Pharma's March 2025 capital increase with support from historical shareholders including Biocodex and PSIM Fund represents the largest single funding event of early 2025. The company simultaneously announced their licensing deal with Clinigen worth €10.5 million upfront plus €18 million in potential milestones, demonstrating both equity and non-dilutive funding strategies.

The MaaT Pharma-Clinigen licensing agreement represents one of the most significant commercial partnerships announced in 2025, providing validation for Microbiome Ecosystem Therapy approaches and establishing precedent for future licensing deal structures. The mid-thirties percentage royalty rate reflects industry standards for innovative therapeutic platforms with proven clinical efficacy.

Enterome's $19 million funding round supports advancement of their microbiome-derived drug discovery platform, while PreciseDx's $11 million additional funding enables expansion of their precision medicine diagnostic capabilities. These transactions indicate continued investor confidence in both therapeutic development and diagnostic platform companies.

Based on disclosed transactions through July 2025, the microbiome therapeutics sector has raised approximately $40-50 million in new funding, suggesting a pace consistent with 2024 activity levels. The focus remains on companies with clinical validation, regulatory clarity, or established commercial partnerships rather than early-stage research platforms.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Are there any public or private market exits in microbiome therapeutics, and who were the buyers or acquirers?

Nestlé Health Science's acquisition of VOWST from Seres Therapeutics for $175 million upfront plus up to $350 million in future milestones represents the most significant exit transaction in microbiome therapeutics history.

This acquisition validated the commercial potential of FDA-approved microbiome therapeutics and provided clear benchmarks for investor return expectations. VOWST became the first oral fecal microbiome product approved for C. difficile infection prevention, demonstrating the pathway from startup innovation to regulatory approval and major corporate acquisition.

Ferring Pharmaceuticals' acquisition of Rebiotix resulted in successful commercialization of the first FDA-approved oral fecal microbiome product, establishing Ferring as a market leader in microbiome therapeutics. This acquisition demonstrates pharmaceutical industry commitment to acquiring companies with proven regulatory pathways and commercial potential.

Public market activity includes several microbiome companies trading on major exchanges: Finch Therapeutics (FNCH) currently trades at a $22 million market capitalization after discontinuing their Phase III C. difficile trial, while BiomX (PHGE) announced a merger with Adaptive Phage Therapeutics plus $50 million concurrent financing. MaaT Pharma trades on Euronext (MAAT) as a European-listed company advancing toward potential EMA approval.

Strategic acquirers beyond pharmaceutical companies include food and nutrition giants: Danone acquired The Akkermansia Company (TAC) for their specialized probiotic strains, while PepsiCo acquired poppi for $1.95 billion, demonstrating corporate interest in consumer-facing microbiome applications. These acquisitions indicate expanding market opportunities beyond traditional pharmaceutical applications into functional foods and consumer health products.

What are experts and analysts predicting in terms of funding trends or firm activity for 2026?

Industry analysts predict the microbiome therapeutics market will reach $3.8 billion by 2026, representing a compound annual growth rate of 20-25% driven by increasing clinical validation, expanding regulatory pathways, and growing pharmaceutical industry adoption.

Venture capital activity is expected to concentrate on fewer, higher-quality companies with experienced management teams and strong scientific data. Series A rounds are anticipated to dominate funding activity, capturing larger deal sizes as investors focus on early-stage companies with validated therapeutic approaches rather than speculative research platforms.

Geographic expansion is predicted to accelerate, with Asia-Pacific emerging as a major growth region driven by China's $400 million National Microbiome Project and Japan's significant government funding initiatives. European investment activity is expected to remain strong, supported by Seventure Partners' continued specialization and government funding programs including Horizon Europe's €60 million "Microbiome in Health and Disease" initiative.

Technology focus areas for 2026 investment include AI-driven microbiome analysis platforms, as artificial intelligence becomes essential for analyzing complex microbiome data and predicting therapeutic outcomes. Combination therapies integrating microbiome interventions with traditional pharmaceuticals are anticipated to gain significant traction, particularly in oncology and immunology applications.

Personalized microbiome medicine is predicted to advance substantially, with companion diagnostics becoming standard for optimizing patient selection and treatment outcomes. Investors are expected to prioritize companies developing integrated platform approaches that combine diagnostics, therapeutics, and data analytics capabilities.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Are there notable incubators, accelerators, or strategic alliances supporting microbiome therapeutics startups right now?

The inaugural Microbiome Accelerator Program, a partnership between Nature Awards and Seed Health, concluded in December 2024 by awarding four research teams $10,000 grants each plus expert mentorship from leading microbiome scientists and entrepreneurs.

Program winners included teams from MD Anderson Cancer Center focusing on cancer microbiome applications, Nanjing University developing novel therapeutic approaches, University of Western Australia advancing microbiome diagnostics, and Duke University School of Medicine creating innovative delivery systems. This specialized accelerator provides validation and early-stage support for academic teams transitioning to commercial applications.

Nucleate, a student-led biotech accelerator founded in 2018, provides comprehensive tools and resources for microbiome entrepreneurs through their growing network of over 5,500 venture investors. The program connects early-stage teams with experienced mentors, potential co-founders, and funding opportunities specifically relevant to biotech startups.

Established biotech accelerators actively supporting microbiome companies include Alchemist Accelerator in San Francisco, which has backed more than 500 companies and helped raise $2.1 billion in total funding. Their portfolio includes drug delivery platform Hera Health Solutions and lab-grown tissue company Frontier Bio, demonstrating support for innovative healthcare technologies including microbiome applications.

Strategic research alliances provide critical support infrastructure: the University of Chicago's microbiome ecosystem has generated three companies (32 Biosciences, Covira, Gateway Biome) with combined NIH support exceeding $119 million. The university's Duchossois Family Institute provides core facilities for microbiome research and product development, creating an integrated support system for startup formation and growth.

Government and non-profit support includes the Bill & Melinda Gates Foundation's $10.4 million strategic investment in Freya Biosciences in November 2024, demonstrating philanthropic interest in microbiome applications for global health challenges. ARPA-H's Sprint for Women's Health awarded $3 million to Ancilia Biosciences for CRISPR-based bacterial therapy development, highlighting government support for innovative microbiome applications in underserved medical areas.

Conclusion

Sources

1. Securities.io - Microbiome Companies
2. Labiotech.eu - Recent Biotech Fundings
3. American Pharmaceutical Review - Microbiome Therapeutics Market Report
4. Global Venturing - Twelve Human Microbiome Startups to Watch
5. Biose.com - Microbiome Investment Analysis
6. Globe Newswire - Microbiome Collaboration and Licensing Agreements
7. Vestbee - Top Health Tech VC Funds
8. Seedtable - MicroBiome Therapeutics
9. Metatech Insights - Microbiome Therapeutics Market
10. F6S - Microbiomics Company Profile
11. Future of Microbiome - Funding Landscape Report
12. MaaT Pharma - Capital Increase Announcement
13. Microbiome Post - MaaT Pharma and Clinigen Partnership
14. University of Chicago - Microbiome Startups Collaboration
15. Seres Therapeutics - VOWST Asset Purchase
16. Venture Radar - Microbiome Therapeutics Funding
17. Fortune Business Insights - Microbiome Therapeutics Market
18. Labiotech.eu - Recent Biotech Deals
19. EnteroBiotix - Series A Funding
20. Microbiome Times - Metagen Therapeutics Series A
21. GM Insights - Microbiome Therapeutics Market Analysis
22. JSR Corporation - Metagen Partnership
23. Markwide Research - Market Forecast